Does Crispr Therapeutics sponsor H-1B workers?
VisaSignal shows official LCA filing activity found in the imported dataset. That activity can indicate historical immigration-related hiring signals, but it is not a promise of sponsorship.
Employer profile
Official filing activity, wage signals, roles, and source freshness in one place.
LCA
12
PERM
0
Median wage
$124,379
Last activity
Mar 31, 2026
Summary
Crispr Therapeutics has filed 12 Labor Condition Applications (LCA) in FY2026 Q2, with all applications certified. The top roles include Principal Research Associate, Manager of Regulatory Affairs, and Senior Medical Director in Pharmacovigilance, primarily located in Boston, MA. Salary data indicates a median of $124,379, with a range from $102,000 to $320,000. Notably, there have been no PERM applications filed, which is relevant for green card processes. Remember, LCA certification does not equate to USCIS H-1B petition approval, and this information is not legal advice.
Sources
Employer filing context
Use this section for searches such as "Crispr Therapeutics H-1B", "Crispr Therapeutics LCA", and "Crispr Therapeutics PERM" before comparing individual case rows.
Activity mix
12 LCA rows and 0 PERM rows are normalized to this employer.
Latest source period: FY2026 Q2.
Role and worksite signal
Top observed role: Principal Research Associate. Top worksite: Boston, MA.
Compare this with the H-1B/LCA and PERM drill-down tabs before treating counts as a hiring signal.
Normalization and source check
Primary source: DOL OFLC disclosure data. Last verified: .
Filing trends
Server-rendered charts from imported DOL OFLC disclosure data. Filing counts are official signals — not sponsorship, hiring, or approval outcomes.
Imported filings by fiscal year
Crispr Therapeutics shows 12 imported H-1B/LCA and PERM filings in FY2026. Counts are imported DOL filing signals, not sponsorship, hiring, or approval outcomes.
| Fiscal year | H-1B/LCA filings | PERM filings | Total filings |
|---|---|---|---|
| FY2026 | 12 | 0 | 12 |
Wage distribution (recent imported records)
Crispr Therapeutics imported wage records (n=12) span $102,000 to $320,000, with a middle 50% from $120,000 to $144,000 and a median of $124,379.
Median $124,379
| Minimum | $102,000 |
|---|---|
| 25th percentile | $120,000 |
| Median | $124,379 |
| 75th percentile | $144,000 |
| Maximum | $320,000 |
| Records | 12 |
Source: DOL OFLC disclosure data, retrieved .
Roles
Worksites
Status mix
LCA and PERM rows are filing signals, not USCIS approvals, green-card approvals, legal advice, or outcome predictions.
FAQ
VisaSignal shows official LCA filing activity found in the imported dataset. That activity can indicate historical immigration-related hiring signals, but it is not a promise of sponsorship.
The PERM count reflects imported DOL PERM disclosure rows for this normalized employer. Raw employer names and aliases are preserved so users can inspect normalization confidence.
For Crispr Therapeutics H-1B research, the page summarizes imported DOL LCA labor-condition rows. For Crispr Therapeutics PERM research, it summarizes imported DOL permanent labor certification rows. Both include roles, worksites, wage signals, case-status mix, and the latest source period.
No. A DOL-certified LCA is not the same as USCIS H-1B petition approval. It is an official labor-condition filing signal that should be interpreted with that limit.
No. PERM certification is one step in an employment-based green card process. It does not mean a green card, I-140 petition, or adjustment of status was approved.
No. Official filing history can show recent activity, roles, worksites, and wage signals, but it does not guarantee future sponsorship or predict legal outcomes.